Acute coronary syndromes

Annals of Emergency Medicine

Volumn 37, Issue 4 SUPPL., 2001, Pages

  Aufderheide, Tom P ^a   Bossaert, Leo L ^b   Field, John ^c   Herlitz, Johan ^d   Leizorovicz, Alain ^e   Littrell, Katherine A ^f   Ornato, Joseph P ^g   Peberdy, Mary Ann ^g   Ribichini, Flavio ^h  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

^d Sahlgrenska Sjukhuset   (Sweden)

^e UNIVERSITÉ DE LYON   (France)

^f GENENTECH INC   (United States)

^g VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Divisione di Cardiologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; GLUCOSE; HEPARIN; INSULIN; POTASSIUM; TIROFIBAN; FIBRINOGEN RECEPTOR;

ANGIOPLASTY; ELECTROCARDIOGRAM; FIBRINOLYTIC THERAPY; HEART MUSCLE ISCHEMIA; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION; UNSTABLE ANGINA PECTORIS; ACUTE DISEASE; ARTICLE; CLASSIFICATION; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; ELECTROCARDIOGRAPHY; EMERGENCY HEALTH SERVICE; EMERGENCY TREATMENT; EVIDENCE BASED MEDICINE; INSTRUMENTATION; METHODOLOGY; MORTALITY; PATIENT SELECTION; STANDARD; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ACUTE DISEASE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; ELECTROCARDIOGRAPHY; EMERGENCY MEDICAL SERVICES; EMERGENCY TREATMENT; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HUMANS; PATIENT SELECTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TIME FACTORS; TREATMENT OUTCOME; TRIAGE;

EID: 0035064119     PISSN: 01960644     EISSN: None     Source Type: Journal    
DOI: 10.1067/mem.2001.114178     Document Type: Article

References (118)

1. ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
2. An evaluation of technologies for identifying acute cardiac ischemia in the emergency department: A report from a National Heart Attack Alert Program Working Group
3. Cellular telephone transmission of 12-lead electrocardiograms from ambulance to hospital
4. The diagnostic impact of prehospital 12-lead electrocardiography
5. A prospective evaluation of prehospital 12-lead ECG application in chest pain patients
6. Milwaukee Prehospital Chest Pain Project - Phase I: Feasibility and accuracy of prehospital thrombolytic candidate selection
7. Feasibility of prehospital r-TPA therapy in chest pain patients
8. Myocardial Infarction Triage and Intervention Project - Phase I: Patient characteristics and feasibility of prehospital initiation of thrombolytic therapy
9. Relative importance of emergency medical system transport and the prehospital electrocardiogram on reducing hospital time delay to therapy for acute myocardial infarction: A preliminary report from the Cincinnati Heart Project
10. Impact of field-transmitted electrocardiography on time to in-hospital thrombolytic therapy in acute myorcadial infarction
11. Accuracy of the portable interpretive ECG machine in diagnosis of acute evolving myocardial infarction
12. Prehospital recognition of AMI using independent nurse/paramedic 12-lead ECG evaluation: Impact on in-hospital times to thrombolysis in a rural community hospital
13. Prevention of myocardial damage in acute myocardial ischemia by early treatment with intravenous streptokinase
14. Importance of early initiation of intravenous streptokinase therapy for acute myocardial infarction
15. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial
16. The prehospital electrocardiogram in acute myocardial infarction: Is its full potential being realized? National Registry of Myocardial Infarction 2 Investigators
17. Thormbolysis started at home in acute myocardial infarction: Feasibility and time-gain
18. Very early thrombolytic therapy in suspected acute myocardial infarction
19. Early reperfusion by initiation of intravenous streptokinase infusion prior to ambulance transport
20. Prehospital use of APSAC: Results of a placebo-controlled study
21. Prehospital thrombolytic treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex
22. Should thrombolytic therapy be administered in the mobile intensive care unit in patients with evolving myocardial infarction? A pilot study
23. Halving of morality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT)
24. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction
25. Prehospital thrombolysis in acute myocardial infarction: The Belgian eminase prehospital study (BEPS)
26. Prehospital thrombolysis in suspected acute myocardial infarction: Results from the TEAHAT Study
27. Prehospital coronary thrombolysis. A new strategy in acute myocardial infarction
28. Cost-effectiveness of prehospital 12-lead ECGs in improving outcome of acute myocardial infarction
29. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary and recommendations: A report of the American College of Cardiology/American Hear Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
30. Myocardial infarction triage and intervention project - Phase I: Patient characteristics and feasibility of prehospital initiation of thrombolytic therapy
31. Rescue angioplasty after failed thrombolysis: Technical and clinical outcomes in a large thrombolysis trial: GUSTO-1 Angiographic Investigators (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries)
32. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alterplase (recombinants tissue-type plasminogen activator) in patients with acute myocardial infarction: A report from the Second National Registry of Myocardial Infarction (NMRI-2)
33. Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an International Registry. SHOCK Registry Investigators
34. Early revascularization in acute myocardial infarction complicated by cardiogenic shock: SHOCK Investigators (Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock)
35. A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction
36. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction
37. Coronary angioplasty as primary therapy for acute myocardial infarction 6 to 48 hours after symptom onset: Report of an initial experience
38. Long-term results of thrombolytic therapy with and without percutaneous transluminal coronary angioplasty
39. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group
40. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction
41. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment of myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups
42. Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction
43. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials
44. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
45. The acute coronary syndromes, including myocardial infarction: Guidelines for the management of patients with possible or probable acute myocardial infarction
46. The prehospital phase of patients with suspected acute myocardial infarct: Results of the Oltner Cardiac Emergency Study
47. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction
48. Comparison of thrombolytic therapy and primary coronary angioplasty with liberal stenting for inferior myocardial infarction with precordial ST-segment depression: Immediate and long-term results of a randomized study
49. Primary angioplasty verus systematic thrombolysis in anterior myocardial infarction
50. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review
51. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial infarction)
52. Effect of reperfusion on biventricular function and survival after right ventricular infarction
53. Long-term outcome after primary angioplasty: Report from the Primary Angiopiasty in Myocardial Infarction (PAMI-I) trial
54. Long-term follow-up after direct percutaneous transluminal coronary angioplasty for acute myocardial infarction
55. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction
56. Randomized comparison of primary coronary angioplasty with thrombolytic therapy in low risk patients with acute myocardial infarction
57. Immediate coronary angioplasty versus intravenous streptokinase in acute myocardial infarction: Left ventricular ejection fraction, hospital mortality and reinfarction
58. Limitation of infarct size and preservation of left ventricular function after primary coronary angioplasty compared with intravenous streptokinase in acute myocardial infarction
59. Long-term beneficial effect of late reperfusion for acute anterior myocardial infarction with percutaneous transluminal coronary angioplasty
60. Reperfusion therapy in cardiogenic shock complicating acute myocardial infarction
61. Reperfusion therapy in cardiogenic shock
62. Direct percutaneous transluminal coronary angioplasty: Which patients in which setting
63. Revisiting reperfusion therapy in inferior myocardial infarction
64. Inferior myocardial infarction: High-risk subgroups
65. Right ventricular infarction as an independent predictor of prognosis after acute inferior myocardial infarction
66. In-hospital outcome of elderly patients with acute inferior myocardial infarction and right ventricular involvement
67. Effects of thrombolytic therapy in acute inferior myocardial infarction with or without right ventricular involvement: HIT-4 Trial Group (Hirudin for Improvement of Thrombolysis)
68. Impact of early accelerated dose tissue plasminogen activator on in-hospital patency of the infarcted vessel in patients with acute right ventricular infarction
69. Treatment of right ventricular infarction: Thrombolytic therapy, coronary angioplasty or neither?
70. Mechanism of acute myocardial infarction in patients with prior coronary artery bypass grafting and therapeutic implications
71. Comparison of results of coronary angioplasty during acute myocardial infarction with and without previous coronary bypass surgery
72. Usefulness of angioplasty during acute myocardial infarction in patients with prior coronary artery bypass grafting
73. Angiographic and clinical outcomes following acute infarct angiopiasty on saphenous vein grafts
74. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction
75. Failed coronary thrombolysis
76. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators
77. Influence of treatment delay on infarct size and clinical outcome in patients with acute myocardial infarction treated with primary angioplasty
78. Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction
79. When should patients with acute myocardial infarction be transferred for primary angioplasty?
80. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: Results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial
81. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction
82. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
83. Should thrombolysis or primary angioplasty be the treatment of choice for acute myocardial infarction? Thrombolysis - The preferred treatment
84. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. Myocardial Infarction Triage and Intervention Investigators
85. Direct percutaneous transluminal coronary angioplasty in acute myocardial infarction. Predictors of short-term outcome and the impact of coronary stenting: Study Group of The Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK)
86. Transferring patients for primary angioplasty: A retrospective analysis of 104 selected high risk patients with acute myocardial infarction
87. The PRAGUE study - A national multicenter randomized study comparing primary angioplasty vs. thrombolysis both in patients with acute myocardial infarction admitted to the community hospitals: Results of the pilot phase
88. A matched comparison of the combination of prehospital thrombolysis and standby rescue angioplasty with primary angioplasty
89. Early referral for intentional rescue PTCA after initiation of thrombolytic therapy in patients admitted to a community hospital because of a large acute myocardial infarction
90. Cost and quality of life: Thrombolysis and primary angioplasty
91. Analysis of the relative costs and effectiveness of primary angioplasty versus tissue-type plasminogen activator: The Primary Angioplasty in Myocardial Infarction (PAMI) trial. The PAMI Trial Investigators
92. Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. PAMI-II Investigators. Primary Angioplasty in Myocardial Infarction
93. Projected cost-effectiveness of primary angioplasty for acute myocardial infarction
94. Cost-effectiveness of reperfusion strategies
95. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
96. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes
97. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
98. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months: The EPIC Investigators
99. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction: EPIC investigators
100. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication
101. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
102. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
103. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
104. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
105. Effects of integrelin, a platelet giycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial
106. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study
107. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIa inhibitor), heparin, or both in unstable angina. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network
108. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group
109. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction: A preliminary clinical report
110. Potassium, glucose, and insulin in treatment of myocardial infarction
111. Reduction of hospital mortality rate of acute myocardial infarction with glucose-insulin-potassium infusion
112. Clinical experience with glucose-insulin-potassium therapy in acute myocardial infarction
113. Use of glucose-insulin-potassium in treating myocardial infarction
114. Randomized trial of insulinglucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year
115. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: An overview of randomized placebo-controlled trials
116. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group
117. Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: Results of a randomized multicenter Pol-GIK trial
118. The use of intraaortic balloon counterpulsation as an adjunct to reperfusion therapy in cardiogenic shock